森 由希子

最終更新日時: 2019/06/04 21:28:55

印刷する

氏名(漢字/フリガナ/アルファベット表記)
森 由希子/モリ ユキコ/Mori, Yukiko
所属部署・職名(部局/所属/講座等/職名)
医学部附属病院/医療情報企画部/特定講師
連絡先住所
種別 住所(日本語) 住所(英語)
職場 京都府京都市左京区聖護院川原町54 54 Shogoin-Kawaharacho,sakyo-ku,kyoto,kyoto
連絡先電話番号
種別 番号
職場 075-751-4770
所属学会(国内)
学会名(日本語) 学会名(英語)
日本臨床腫瘍学会
日本癌治療学会
日本外科学会
日本内科学会
日本癌学会
日本消化器外科学会
所属学会(海外)
学会名(英語) 国名
ASCO
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
博士(医学) 京都大学 Kyoto University
出身大学院・研究科等
大学名(日本語) 大学名(英語) 研究科名(日本語) 研究科名(英語) 専攻名(日本語) 専攻名(英語) 修了区分
京都大学 大学院医学研究科博士課程外科系専攻 修了
出身学校・専攻等
大学名(日本語) 大学名(英語) 学部名(日本語) 学部名(英語) 学科名(日本語) 学科名(英語) 卒業区分
滋賀医科大学 医学部医学科 卒業
プロフィール
(日本語)
滋賀医科大学卒業後、京都大学外科に所属。 大学院卒業後、腫瘍内科医として主に化学療法に従事。 2016年より厚生労働省医系技官として人事交流 2018年より、診療、研究に復帰
researchmap URL
https://researchmap.jp/7000009008
研究テーマ
(日本語)
本邦のがん患者の治療実態調査、NDB databaseを利用したリアルワールドデータ研究、食道癌術後患者における食思関連ホルモン変動、抗がん薬アレルギー反応、中心静脈ポートの安全性の評価
(英語)
real-world reserch using NDB database,allergy to anti-cancer drug,central venous port
研究概要
(日本語)
現在、NDBの提供をうけ、本邦のがん患者の治療実態調査を行っている。
研究分野(キーワード)
キーワード(日本語) キーワード(英語)
臨床腫瘍学
薬物動態
有害事象予測
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, Kadokawa Y, Yamanokuchi S, Kawamura J, Zaima M, Kyogoku T, Kanazawa A, Mori Y, Kanai M, Matsumoto S, Sakai Y Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, Kadokawa Y, Yamanokuchi S, Kawamura J, Zaima M, Kyogoku T, Kanazawa A, Mori Y, Kanai M, Matsumoto S, Sakai Y Hasegawa S, Goto S, Matsumoto T, Hida K, Kawada K, Matsusue R, Yamaguchi T, Nishitai R, Manaka D, Kato S, Kadokawa Y, Yamanokuchi S, Kawamura J, Zaima M, Kyogoku T, Kanazawa A, Mori Y, Kanai M, Matsumoto S, Sakai Y A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. Annals of surgical oncology, 24, 12, 3587-3595 Annals of surgical oncology, 24, 12, 3587-3595 Annals of surgical oncology, 24, 12, 3587-3595 2017/11 公開
Aizawa R, Matsumoto S, Uneno Y, Nishikawa Y, Ozaki Y, Mori Y, Kanai M, Ishida Y, Sakanaka K, Hiraoka M, Muto M Aizawa R, Matsumoto S, Uneno Y, Nishikawa Y, Ozaki Y, Mori Y, Kanai M, Ishida Y, Sakanaka K, Hiraoka M, Muto M Aizawa R, Matsumoto S, Uneno Y, Nishikawa Y, Ozaki Y, Mori Y, Kanai M, Ishida Y, Sakanaka K, Hiraoka M, Muto M Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer. Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer. Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer. Japanese journal of clinical oncology, 47, 9, 885-888 Japanese journal of clinical oncology, 47, 9, 885-888 Japanese journal of clinical oncology, 47, 9, 885-888 2017/09 公開
Nishikawa Y, Kanai M, Narahara M, Tamon A, Brown JB, Taneishi K, Nakatsui M, Okamoto K, Uneno Y, Yamaguchi D, Tomono T, Mori Y, Matsumoto S, Okuno Y, Muto M Nishikawa Y, Kanai M, Narahara M, Tamon A, Brown JB, Taneishi K, Nakatsui M, Okamoto K, Uneno Y, Yamaguchi D, Tomono T, Mori Y, Matsumoto S, Okuno Y, Muto M Nishikawa Y, Kanai M, Narahara M, Tamon A, Brown JB, Taneishi K, Nakatsui M, Okamoto K, Uneno Y, Yamaguchi D, Tomono T, Mori Y, Matsumoto S, Okuno Y, Muto M Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population. Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population. Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population. International journal of clinical oncology, 22, 2, 269-273 International journal of clinical oncology, 22, 2, 269-273 International journal of clinical oncology, 22, 2, 269-273 2017/04 公開
Mori Y, Nagayama S, Kawamura J, Hasegawa S, Tanaka E, Okabe H, Takeuchi M, Sonobe M, Matsumoto S, Kanai M, Muto M, Chiba T, Sakai Y Mori Y, Nagayama S, Kawamura J, Hasegawa S, Tanaka E, Okabe H, Takeuchi M, Sonobe M, Matsumoto S, Kanai M, Muto M, Chiba T, Sakai Y Mori Y, Nagayama S, Kawamura J, Hasegawa S, Tanaka E, Okabe H, Takeuchi M, Sonobe M, Matsumoto S, Kanai M, Muto M, Chiba T, Sakai Y A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute. A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute. A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute. International journal of clinical oncology, 21, 3, 474-482 International journal of clinical oncology, 21, 3, 474-482 International journal of clinical oncology, 21, 3, 474-482 2016/06 公開
Uneno Y, Yokoyama A, Nishikawa Y, Funakoshi T, Ozaki Y, Aoyama I, Baba K, Yamaguchi D, Morita S, Mori Y, Kanai M, Kinoshita H, Inoue T, Sawamoto N, Matsumoto R, Matsumoto S, Muto M Uneno Y, Yokoyama A, Nishikawa Y, Funakoshi T, Ozaki Y, Aoyama I, Baba K, Yamaguchi D, Morita S, Mori Y, Kanai M, Kinoshita H, Inoue T, Sawamoto N, Matsumoto R, Matsumoto S, Muto M Uneno Y, Yokoyama A, Nishikawa Y, Funakoshi T, Ozaki Y, Aoyama I, Baba K, Yamaguchi D, Morita S, Mori Y, Kanai M, Kinoshita H, Inoue T, Sawamoto N, Matsumoto R, Matsumoto S, Muto M Paraneoplastic Limbic Encephalitis in a Human Epidermal Growth Factor Receptor-2-positive Gastric Cancer Patient Treated with Trastuzumab-combined Chemotherapy: A Case Report and Literature Review. Paraneoplastic Limbic Encephalitis in a Human Epidermal Growth Factor Receptor-2-positive Gastric Cancer Patient Treated with Trastuzumab-combined Chemotherapy: A Case Report and Literature Review. Paraneoplastic Limbic Encephalitis in a Human Epidermal Growth Factor Receptor-2-positive Gastric Cancer Patient Treated with Trastuzumab-combined Chemotherapy: A Case Report and Literature Review. Internal medicine (Tokyo, Japan), 55, 18, 2605-2609 Internal medicine (Tokyo, Japan), 55, 18, 2605-2609 Internal medicine (Tokyo, Japan), 55, 18, 2605-2609 2016 公開
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33, 34, 4015-4022 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33, 34, 4015-4022 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33, 34, 4015-4022 2015/12 公開
Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. International journal of clinical oncology, 21, 1, 118-125 International journal of clinical oncology, 21, 1, 118-125 International journal of clinical oncology, 21, 1, 118-125 2015/06 公開
Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Pancreas, 43, 3, 411-416 Pancreas, 43, 3, 411-416 Pancreas, 43, 3, 411-416 2014/04 公開
Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer medicine, 3, 2, 406-415 Cancer medicine, 3, 2, 406-415 Cancer medicine, 3, 2, 406-415 2014/04 公開
H. Nagai; T. Kitano; T. Nishimura; H. Yasuda; K. Nakata; S. Takashima; M. Kanai; S. Matsumoto; Y. Mori; Y. Kakudo; H. Sato; T. Yamaguchi; K. Kameno; Y.H. Kim; M. Mishima; K. Yanagihara H. Nagai; T. Kitano; T. Nishimura; H. Yasuda; K. Nakata; S. Takashima; M. Kanai; S. Matsumoto; Y. Mori; Y. Kakudo; H. Sato; T. Yamaguchi; K. Kameno; Y.H. Kim; M. Mishima; K. Yanagihara H. Nagai; T. Kitano; T. Nishimura; H. Yasuda; K. Nakata; S. Takashima; M. Kanai; S. Matsumoto; Y. Mori; Y. Kakudo; H. Sato; T. Yamaguchi; K. Kameno; Y.H. Kim; M. Mishima; K. Yanagihara Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: A double-blind randomized crossover study Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: A double-blind randomized crossover study Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: A double-blind randomized crossover study Supportive Care in Cancer, 21, 12, 3271-3278 Supportive Care in Cancer, 21, 12, 3271-3278 Supportive Care in Cancer, 21, 12, 3271-3278 2013/12 英語 公開
M. Kanai; Y. Otsuka; K. Otsuka; M. Sato; T. Nishimura; Y. Mori; M. Kawaguchi; E. Hatano; Y. Kodama; S. Matsumoto; Y. Murakami; A. Imaizumi; T. Chiba; J. Nishihira; H. Shibata M. Kanai; Y. Otsuka; K. Otsuka; M. Sato; T. Nishimura; Y. Mori; M. Kawaguchi; E. Hatano; Y. Kodama; S. Matsumoto; Y. Murakami; A. Imaizumi; T. Chiba; J. Nishihira; H. Shibata M. Kanai; Y. Otsuka; K. Otsuka; M. Sato; T. Nishimura; Y. Mori; M. Kawaguchi; E. Hatano; Y. Kodama; S. Matsumoto; Y. Murakami; A. Imaizumi; T. Chiba; J. Nishihira; H. Shibata A phase i study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients A phase i study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients A phase i study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients Cancer Chemotherapy and Pharmacology, 71, 6, 1521-1530 Cancer Chemotherapy and Pharmacology, 71, 6, 1521-1530 Cancer Chemotherapy and Pharmacology, 71, 6, 1521-1530 2013/06 英語 公開
G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer Angiogenesis, 15, 1, 141-150 Angiogenesis, 15, 1, 141-150 Angiogenesis, 15, 1, 141-150 2012/03 英語 公開
M. Kanai; K. Yoshimura; M. Asada; A. Imaizumi; C. Suzuki; S. Matsumoto; T. Nishimura; Y. Mori; T. Masui; Y. Kawaguchi; K. Yanagihara; S. Yazumi; T. Chiba; S. Guha; B.B. Aggarwal M. Kanai; K. Yoshimura; M. Asada; A. Imaizumi; C. Suzuki; S. Matsumoto; T. Nishimura; Y. Mori; T. Masui; Y. Kawaguchi; K. Yanagihara; S. Yazumi; T. Chiba; S. Guha; B.B. Aggarwal M. Kanai; K. Yoshimura; M. Asada; A. Imaizumi; C. Suzuki; S. Matsumoto; T. Nishimura; Y. Mori; T. Masui; Y. Kawaguchi; K. Yanagihara; S. Yazumi; T. Chiba; S. Guha; B.B. Aggarwal A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer Cancer Chemotherapy and Pharmacology, 68, 1, 157-164 Cancer Chemotherapy and Pharmacology, 68, 1, 157-164 Cancer Chemotherapy and Pharmacology, 68, 1, 157-164 2011/07 英語 公開
M. Kanai; K. Yoshimura; T. Tsumura; M. Asada; C. Suzuki; M. Niimi; S. Matsumoto; T. Nishimura; T. Nitta; K. Yasuchika; K. Taura; Y. Mori; A. Hamada; N. Inoue; S. Tada; K. Yanagihara; S. Yazumi; Y. Osaki; T. Chiba; I. Ikai; M. Fukushima; S. Uemoto; E. Hatano M. Kanai; K. Yoshimura; T. Tsumura; M. Asada; C. Suzuki; M. Niimi; S. Matsumoto; T. Nishimura; T. Nitta; K. Yasuchika; K. Taura; Y. Mori; A. Hamada; N. Inoue; S. Tada; K. Yanagihara; S. Yazumi; Y. Osaki; T. Chiba; I. Ikai; M. Fukushima; S. Uemoto; E. Hatano M. Kanai; K. Yoshimura; T. Tsumura; M. Asada; C. Suzuki; M. Niimi; S. Matsumoto; T. Nishimura; T. Nitta; K. Yasuchika; K. Taura; Y. Mori; A. Hamada; N. Inoue; S. Tada; K. Yanagihara; S. Yazumi; Y. Osaki; T. Chiba; I. Ikai; M. Fukushima; S. Uemoto; E. Hatano A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer Cancer Chemotherapy and Pharmacology, 67, 6, 1429-1434 Cancer Chemotherapy and Pharmacology, 67, 6, 1429-1434 Cancer Chemotherapy and Pharmacology, 67, 6, 1429-1434 2011/06 英語 公開
C. Zaima; M. Kanai; S. Ishikawa; Y. Kawaguchi; T. Masui; Y. Mori; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; T. Mimori C. Zaima; M. Kanai; S. Ishikawa; Y. Kawaguchi; T. Masui; Y. Mori; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; T. Mimori C. Zaima; M. Kanai; S. Ishikawa; Y. Kawaguchi; T. Masui; Y. Mori; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; T. Mimori A Case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis A Case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis A Case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis Japanese Journal of Clinical Oncology, 41, 6, 803-806 Japanese Journal of Clinical Oncology, 41, 6, 803-806 Japanese Journal of Clinical Oncology, 41, 6, 803-806 2011/06 英語 公開
M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer British Journal of Cancer, 105, 11, 1693-1696 British Journal of Cancer, 105, 11, 1693-1696 British Journal of Cancer, 105, 11, 1693-1696 2011 英語 公開
R. Takahashi; S. Nagayama; Y. Mori; H. Isoda; A. Yoshizawa; T. Manabe; Y. Sakai R. Takahashi; S. Nagayama; Y. Mori; H. Isoda; A. Yoshizawa; T. Manabe; Y. Sakai R. Takahashi; S. Nagayama; Y. Mori; H. Isoda; A. Yoshizawa; T. Manabe; Y. Sakai A large cystic gastrointestinal stromal tumor of the rectum in the retrorectal space A large cystic gastrointestinal stromal tumor of the rectum in the retrorectal space A large cystic gastrointestinal stromal tumor of the rectum in the retrorectal space International Journal of Clinical Oncology, 15, 6, 601-607 International Journal of Clinical Oncology, 15, 6, 601-607 International Journal of Clinical Oncology, 15, 6, 601-607 2010/12 英語 公開
Y. Okuchi; S. Nagayama; Y. Mori; J. Kawamura; S. Matsumoto; T. Nishimura; A. Yoshizawa; Y. Sakai Y. Okuchi; S. Nagayama; Y. Mori; J. Kawamura; S. Matsumoto; T. Nishimura; A. Yoshizawa; Y. Sakai Y. Okuchi; S. Nagayama; Y. Mori; J. Kawamura; S. Matsumoto; T. Nishimura; A. Yoshizawa; Y. Sakai VEGF hypersecretion as a plausible mechanism for pseudo-meigs\\' syndrome in advanced colorectal cancer VEGF hypersecretion as a plausible mechanism for pseudo-meigs\\' syndrome in advanced colorectal cancer VEGF hypersecretion as a plausible mechanism for pseudo-meigs\\' syndrome in advanced colorectal cancer Japanese Journal of Clinical Oncology, 40, 5, 476-481 Japanese Journal of Clinical Oncology, 40, 5, 476-481 Japanese Journal of Clinical Oncology, 40, 5, 476-481 2010/05 英語 公開
M. Kanai; A. Yoshioka; S. Tanaka; S. Nagayama; S. Matsumoto; T. Nishimura; M. Niimi; S. Teramukai; R. Takahashi; Y. Mori; T. Kitano; H. Ishiguro; K. Yanagihara; T. Chiba; M. Fukushima; F. Matsuda M. Kanai; A. Yoshioka; S. Tanaka; S. Nagayama; S. Matsumoto; T. Nishimura; M. Niimi; S. Teramukai; R. Takahashi; Y. Mori; T. Kitano; H. Ishiguro; K. Yanagihara; T. Chiba; M. Fukushima; F. Matsuda M. Kanai; A. Yoshioka; S. Tanaka; S. Nagayama; S. Matsumoto; T. Nishimura; M. Niimi; S. Teramukai; R. Takahashi; Y. Mori; T. Kitano; H. Ishiguro; K. Yanagihara; T. Chiba; M. Fukushima; F. Matsuda Associations between glutathione S-transferase π Ile<sup>105</sup>Val and glyoxylate aminotransferase Pro<sup>11</sup>Leu and Ile<sup>340</sup>Met polymorphisms and early-onset oxaliplatin-induced neuropathy Associations between glutathione S-transferase π Ile<sup>105</sup>Val and glyoxylate aminotransferase Pro<sup>11</sup>Leu and Ile<sup>340</sup>Met polymorphisms and early-onset oxaliplatin-induced neuropathy Associations between glutathione S-transferase π Ile<sup>105</sup>Val and glyoxylate aminotransferase Pro<sup>11</sup>Leu and Ile<sup>340</sup>Met polymorphisms and early-onset oxaliplatin-induced neuropathy Cancer Epidemiology, 34, 2, 189-193 Cancer Epidemiology, 34, 2, 189-193 Cancer Epidemiology, 34, 2, 189-193 2010/04 英語 公開
Y. Mori; T. Nishimura; T. Kitano; K.-I. Yoshimura; S. Matsumoto; M. Kanai; M. Hazama; H. Ishiguro; S. Nagayama; K. Yanagihara; S. Teramukai; T. Chiba; Y. Sakai; M. Fukushima Y. Mori; T. Nishimura; T. Kitano; K.-I. Yoshimura; S. Matsumoto; M. Kanai; M. Hazama; H. Ishiguro; S. Nagayama; K. Yanagihara; S. Teramukai; T. Chiba; Y. Sakai; M. Fukushima Y. Mori; T. Nishimura; T. Kitano; K.-I. Yoshimura; S. Matsumoto; M. Kanai; M. Hazama; H. Ishiguro; S. Nagayama; K. Yanagihara; S. Teramukai; T. Chiba; Y. Sakai; M. Fukushima Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX Oncology, 79, 1-2, 136-143 Oncology, 79, 1-2, 136-143 Oncology, 79, 1-2, 136-143 2010 英語 公開
K. Okoshi; S. Nagayama; M. Furu; Y. Mori; A. Yoshizawa; J. Toguchida; Y. Sakai K. Okoshi; S. Nagayama; M. Furu; Y. Mori; A. Yoshizawa; J. Toguchida; Y. Sakai K. Okoshi; S. Nagayama; M. Furu; Y. Mori; A. Yoshizawa; J. Toguchida; Y. Sakai A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6 A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6 A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6 Japanese Journal of Clinical Oncology, 39, 8, 528-533 Japanese Journal of Clinical Oncology, 39, 8, 528-533 Japanese Journal of Clinical Oncology, 39, 8, 528-533 2009/08 英語 公開
A. Itami; K. Iguchi; S. Nagayama; A. Nomura; J. Kawamura; Y. Mori; Y. Sakai A. Itami; K. Iguchi; S. Nagayama; A. Nomura; J. Kawamura; Y. Mori; Y. Sakai A. Itami; K. Iguchi; S. Nagayama; A. Nomura; J. Kawamura; Y. Mori; Y. Sakai A case of ascending colon cancer accompanied by suspected portal vein tumor thrombosis with long-term survival who received systemic chemotherapy followed by resection of primary lesion A case of ascending colon cancer accompanied by suspected portal vein tumor thrombosis with long-term survival who received systemic chemotherapy followed by resection of primary lesion A case of ascending colon cancer accompanied by suspected portal vein tumor thrombosis with long-term survival who received systemic chemotherapy followed by resection of primary lesion Japanese Journal of Gastroenterological Surgery, 42, 1, 112-117 Japanese Journal of Gastroenterological Surgery, 42, 1, 112-117 Japanese Journal of Gastroenterological Surgery, 42, 1, 112-117 2009 英語 公開
S. Matsumoto; T. Nishimura; M. Kanai; Y. Mori; S. Nagayama; J. Kawamura; A. Nomura; S. Miyamoto; T. Kitano; H. Ishiguro; K. Yanagihara; S. Teramukai; Y. Sakai; T. Chiba; M. Fukushima S. Matsumoto; T. Nishimura; M. Kanai; Y. Mori; S. Nagayama; J. Kawamura; A. Nomura; S. Miyamoto; T. Kitano; H. Ishiguro; K. Yanagihara; S. Teramukai; Y. Sakai; T. Chiba; M. Fukushima S. Matsumoto; T. Nishimura; M. Kanai; Y. Mori; S. Nagayama; J. Kawamura; A. Nomura; S. Miyamoto; T. Kitano; H. Ishiguro; K. Yanagihara; S. Teramukai; Y. Sakai; T. Chiba; M. Fukushima Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer: A single-institution outcome study Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer: A single-institution outcome study Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer: A single-institution outcome study Chemotherapy, 54, 5, 395-403 Chemotherapy, 54, 5, 395-403 Chemotherapy, 54, 5, 395-403 2008 英語 公開
Y. Mori; T. Okumura; S. Tsunoda; Y. Sakai; Y. Shimada Y. Mori; T. Okumura; S. Tsunoda; Y. Sakai; Y. Shimada Y. Mori; T. Okumura; S. Tsunoda; Y. Sakai; Y. Shimada Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma Oncology, 70, 5, 378-389 Oncology, 70, 5, 378-389 Oncology, 70, 5, 378-389 2007 英語 公開
S. Tsunoda; T. Okumura; T. Ito; Y. Mori; T. Soma; G. Watanabe; J. Kaganoi; A. Itami; Y. Sakai; Y. Shimada S. Tsunoda; T. Okumura; T. Ito; Y. Mori; T. Soma; G. Watanabe; J. Kaganoi; A. Itami; Y. Sakai; Y. Shimada S. Tsunoda; T. Okumura; T. Ito; Y. Mori; T. Soma; G. Watanabe; J. Kaganoi; A. Itami; Y. Sakai; Y. Shimada Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma British Journal of Cancer, 95, 3, 322-330 British Journal of Cancer, 95, 3, 322-330 British Journal of Cancer, 95, 3, 322-330 2006 英語 公開
T. Okumura; S. Tsunoda; Y. Mori; T. Ito; K. Kikuchi; T.C. Wang; S. Yasumoto; Y. Shimada T. Okumura; S. Tsunoda; Y. Mori; T. Ito; K. Kikuchi; T.C. Wang; S. Yasumoto; Y. Shimada T. Okumura; S. Tsunoda; Y. Mori; T. Ito; K. Kikuchi; T.C. Wang; S. Yasumoto; Y. Shimada The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma Clinical Cancer Research, 12, 17, 5096-5103 Clinical Cancer Research, 12, 17, 5096-5103 Clinical Cancer Research, 12, 17, 5096-5103 2006 英語 公開
Y. Shimada; G. Watanabe; J. Kawamura; T. Soma; M. Okabe; T. Ito; H. Inoue; M. Kondo; Y. Mori; E. Tanaka; M. Imamura Y. Shimada; G. Watanabe; J. Kawamura; T. Soma; M. Okabe; T. Ito; H. Inoue; M. Kondo; Y. Mori; E. Tanaka; M. Imamura Y. Shimada; G. Watanabe; J. Kawamura; T. Soma; M. Okabe; T. Ito; H. Inoue; M. Kondo; Y. Mori; E. Tanaka; M. Imamura Clinical significance of osteopontin in esophageal squamous cell carcinoma: Comparison with common tumor markers Clinical significance of osteopontin in esophageal squamous cell carcinoma: Comparison with common tumor markers Clinical significance of osteopontin in esophageal squamous cell carcinoma: Comparison with common tumor markers Oncology, 68, 2-3, 285-292 Oncology, 68, 2-3, 285-292 Oncology, 68, 2-3, 285-292 2005 英語 公開

  • <<
  • >>
  • 表示
タイトル言語:
外部資金:競争的資金・科学研究費補助金
種別 代表/分担 テーマ(日本語) テーマ(英語) 期間
若手研究(B) 代表 食道亜全摘手術後の食思関連ホルモンの動向:グレリン高値のパラドックスの解析 2008〜2009
部局運営(役職等)
役職名 期間
ICT